Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCL

NCT06468943 · clinicaltrials.gov ↗

PHASE2

Phase

ENROLLING_BY_INVITATION

Status

20

Enrollment

OTHER

Sponsor class

Conditions

Effects of Chemotherapy
Safety Issues

Interventions

DRUG: Polatuzumab Vedotin
DRUG: Zanubrutinib
DRUG: Rituximab
DRUG: Cyclophosphamide
DRUG: Doxorubicin
DRUG: Prednisone

Sponsor

The First Affiliated Hospital of Soochow University